Related Experiment Video

Updated: Aug 19, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Activity of cytochrome P450 in children

V A Vavilin1, E G Shchepotina, N A Manankin

  • 1Institute of Molecular Biology and Biophysics, Siberian Division of the Russian Academy of Medical Sciences, Novosibirsk, Russia. drugmet@soramn.ru

Bulletin of Experimental Biology and Medicine
|January 25, 2005
PubMed

Insights

The 6beta-hydroxycortisol/cortisol ratio in children shows the most significant increase between 1.1 and 2.0 years old. This pediatric biomarker study highlights early developmental changes in cortisol metabolism.

Area of Science:

  • Pediatric endocrinology
  • Biomarker research
  • Cortisol metabolism

Background:

  • The 6beta-hydroxycortisol/cortisol ratio is a biomarker for cytochrome P450 activity.
  • Understanding pediatric cortisol metabolism is crucial for assessing endocrine function.
  • Limited data exists on the developmental trajectory of this ratio in early childhood.

Purpose of the Study:

  • To investigate the age-related changes in the 6beta-hydroxycortisol/cortisol ratio in children.
  • To identify the specific age intervals with the most significant alterations in this ratio.
  • To establish reference values for the 6beta-hydroxycortisol/cortisol ratio across different pediatric age groups.

Main Methods:

  • Measurement of the 6beta-hydroxycortisol/cortisol ratio in a cohort of 52 children.
  • Age range of participants: 1.1 to 14.0 years.
  • Statistical analysis using linear and nonlinear logarithmic regression models.

Main Results:

  • The maximum increment in the 6beta-hydroxycortisol/cortisol ratio was observed in children aged 1.1–2.0 years.
  • Regression analyses showed similar coefficients (linear: r=0.57, p=0.044; logarithmic: r=0.56, p=0.049) during this peak increment period.
  • By ages 10–14 years, the ratio reached a mean of 19.17 ± 17.79.

Conclusions:

  • The 6beta-hydroxycortisol/cortisol ratio undergoes substantial changes during early childhood, particularly between 1.1 and 2.0 years.
  • This ratio may serve as a sensitive indicator of early developmental changes in pediatric drug metabolism and steroidogenesis.
  • Further research is warranted to explore the clinical implications of these findings in pediatric populations.

More Related Videos

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling09:33

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling

Published on: March 20, 2018

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Bioactivation and Tissue Toxicity01:25

Bioactivation and Tissue Toxicity

Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...